Abstract:Rheumatoid arthritis (RA) is a common chronic systemic autoimmune disease. Although there are a variety of treatments for RA, the substantial clinical therapies are still limited to disease-modifying anti-rheumatic drugs (DMARD), which would induce obvious side-effect in patients after long-term administration. Herein, an uncomplicated drug-induced self-assembly strategy was proposed to fabricate enzyme-loaded albumin nanomedicine. The hydrophobic drug methotrexate (MTX) could induce self-assembly of superoxide dismutase (SOD) and human serum albumin (HSA) to form HSA-SOD-MTX nanoparticle. After intravenous injection, dual-modal imaging including fluorescence imaging or single-photon emission computed tomography (SPECT)/CT imaging exhibits high accumulation of cyanine 5.5 (Cy5.5) or 125I labeled HSA-SOD-MTX nanoparticles in the joints of collagen-induced arthritis (CIA) mice. Importantly, using the synergy therapy of SOD enzyme to scavenge the reactive oxygen species (ROS) and MTX to suppress inflammation, HSA-SOD-MTX nanoparticles exhibit excellent therapeutic efficiency of RA in CIA mice compared with the other groups. Micro-CT and clinical arthritis score of RA mice further demonstrate that RA symptoms of mice treated with HSA-SOD-MTX nanoparticles is significantly relived, which was further demonstrated by the histological analysis and the inflammatory factors measurement. The synergy therapy of inflammation by MTX and SOD enzyme based on HSA-SOD-MTX nanoparticles show excellent therapeutic effects of RA without inducing obvious side effects. Therefore, our strategy may further promote the highly efficient therapy of RA using SOD enzyme to scavenge the ROS and decreasing the side-effect of MTX, which may provide the reference for clinical RA treatment.

What problem does this paper attempt to address?

This paper attempts to address several key issues in the treatment of Rheumatoid Arthritis (RA): 1. **Limitations of existing treatments**: Although there are many methods to treat RA currently, the main treatments are still limited to disease-modifying antirheumatic drugs (DMARDs), which may cause significant side effects with long-term use. 2. **Inflammation suppression and antioxidant stress**: The pathological features of RA include excessive synovial hyperplasia and granulation tissue formation, which can lead to irreversible damage to joint cartilage and bone tissue. The infiltration of inflammatory cells (especially macrophages) in the joint cavity is key to the immune response. Activation of macrophages produces pro-inflammatory factors such as IL-1β and TNF-α, further amplifying the inflammatory response. Therefore, inhibiting the secretion of inflammatory factors by macrophages is considered an important strategy to alleviate RA. 3. **Side effects of Methotrexate**: Methotrexate (MTX) is currently used to inhibit the secretion of inflammatory cells, but long-term use of MTX may lead to apoptosis of cells in other organs, causing systemic side effects. 4. **Challenges in the application of Superoxide Dismutase (SOD)**: SOD can scavenge reactive oxygen species (ROS), reduce oxidative stress, and prevent cell apoptosis. In synovial fibroblasts of transgenic mice, SOD can inhibit the expression of pro-inflammatory factors. However, SOD faces issues such as poor targeting and limited efficacy in clinical applications, necessitating the development of effective carriers to deliver SOD to the disease site. To address the above issues, this study designed a nano drug delivery system based on human serum albumin (HSA), which can load SOD and MTX and form HSA-SOD-MTX nanoparticles through self-assembly. These nanoparticles can efficiently accumulate in RA joints in vivo through the ELVIS effect, utilizing the synergistic effects of SOD scavenging ROS and MTX inhibiting inflammation, significantly improving the therapeutic effect of RA while reducing the side effects of MTX.

Albumin mediated reactive oxygen species scavenging and targeted delivery of methotrexate for rheumatoid arthritis therapy